The PureTech group company – which scored the first FDA and EMA approvals for a DTx for attention-deficit hyperactivity disorder (ADHD) – is developing AKL-T01 to tackle cognitive impairments that can affect people with SLE.
Cognitive dysfunction occurs in between 20% and 80% of patients with SLE, which causes an autoimmune reaction against multiple organ systems and can have devastating consequences on patients. Around 1.5 million people in the US are living with SLE.
